| 0 Comments |

810-P: Patient-reported outcomes in T2D patients inadequately controlled by metformin are more favorable for dapagliflozin plus saxagliptin vs. insulin glargine.

MARCIA A. TESTA, DONALD C. SIMONSON, ELLA EKHOLM, MAXWELL SU, EVA K. JOHNSSON, Boston, MA, Mölndal, Sweden Patient-Reported Outcomes.
| 0 Comments |

1520-P:  Impact of Patient-Centered Factors on Comparative Effectiveness of Initial Therapies in Treatment-Naïve T2D

MARCIA A. TESTA, ALEXANDER TURCHIN, MAXWELL SU, DONALD C. SIMONSON, Boston, MA Impact of Patient-Centered Factors on Comparative Effectiveness.
| 0 Comments |

941-P: Continuous Glucose Monitoring (CGM) Provides Enhanced Sensitivity Compared with Self-Monitored Blood Glucose (SMBG) for Detecting Hypoglycemia during T2D Clinical Trials.

MARCIA A. TESTA, SERGIO SALDIVAR-SALAZAR, MAXWELL SU, JOHANNA F. HAYES, DONALD C. SIMONSON, Boston, MA, Wellesley Hills, MA Continuous.
| 0 Comments |

905-P: Continuous Glucose Monitoring Glycemic Variability Profiles Are More Favorable for Dapagliflozin plus Saxagliptin Compared with Insulin Glargine in Type 2 Diabetes.

DONALD C. SIMONSON, TINA VILSBØLL, ELLA EKHOLM, EVA K. JOHNSSON, MARCIA A. TESTA, SERGE JABBOUR, MARCUS LIND, Boston, MA,.